Naltrexone in the Treatment of Ketamine Use Disorders: A Case Report and Literature Review (Verma, et al, 2025)
"findings consistent w/ 2 prior reports - use of naltrexone in KUDs at the dosage of 50 mg/day successfully helped patients achieve abstinence... naltrexone reduces antidepressant effects of ketamine, indicating overlap between opioid system & ketamine's NMDA receptor activity. "
Spotlight: Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring (in mice)
"we show that both parous parents and their children may be uniquely vulnerable to psychedelic treatment during the postpartum period"
Spotlight: The transformational power of psychedelics: catalysts for creativity, consciousness, and mental health (Du, et al, 2025)
"Psychedelics, such as psilocybin, lysergic acid diethylamide (LSD), ketamine, and N,N-dimethyltryptamine (DMT), have captured the attention of scientists, artists, and seekers alike for their profound ability to alter consciousness and inspire creativity."
Spotlight: Efficacy of Intravenous Racemic Ketamine on Global Severity and Individual Symptoms of Depression: An Exploratory Retrospective Analysis (Landrum, et al, 2025)
" Maintenance intravenous racemic ketamine therapy demonstrated significant, persistent, and broad efficacy for treatment-resistant depression ...Side effect burden was no greater in higher doses as compared with lower. "
Spotlight: Key competencies for psychedelic treatment in real-world mental health care settings (Wolff, et al, 2025)
"To accommodate mainstream adoption of these treatments, the competencies framework we present respects the distinctive contextual and cultural sensitivities of psychedelic care while remaining anchored in established psychotherapeutic, medical, and scientific paradigms."
Spotlight: Charting a New Frontier: Integrating Cognitive Behavioral Therapy Approaches with 3,4-methylenedioxymethamphetamine (MDMA)
"Psychedelics are being integrated with established cognitive behavioral therapies (CBTs).MDMA is a focus of recent research of psychedelic-assisted cognitive behavioral therapy.Six papers explore interesting and important questions on how to leverage the potential of psychedelics to augment CBTs."